tbuckley/cabot-search huggingface dataset:
Curious? The relationship between curiosity and creativity is likely NOT novelty
Authors: Jamie J. Jirout, Natalie S. Evans, Kathy Hirsh-Pasek
Journal: Behavioral and Brain Sciences (2024)

Abstract The target article tackles an important and complicated issue of the underlying links between curiosity and creativity. Although thought-provoking, the target article overlooks contemporary theories and research on these constructs. Consequently, the proposed model is inconsistent with prior research in the developmental and educational fields and would benefit from better specification and clarity around key constructs and processes.
Oral administration microrobots for drug delivery
Authors: An Ren, Jiarui Hu, Changwei Qin, Neng Xia, Mengfei Yu, Xiaobin Xu, Huayong Yang, Min Han, Li Zhang, Liang Ma
Journal: Bioactive Materials (2024)

Oral administration is the most simple, noninvasive, convenient treatment. With the increasing demands on the targeted drug delivery, the traditional oral treatment now is facing some challenges: 1) biologics how to implement the oral treatment and ensure the bioavailability is not lower than the subcutaneous injections; 2) How to achieve targeted therapy of some drugs in the gastrointestinal tract? Based on these two issues, drug delivery microrobots have shown great application prospect in oral drug delivery due to their characteristics of flexible locomotion or driven ability. Therefore, this paper summarizes various drug delivery microrobots developed in recent years and divides them into four categories according to different driving modes: magnetic-controlled drug delivery microrobots, anchored drug delivery microrobots, self-propelled drug delivery microrobots and biohybrid drug delivery microrobots. As oral drug delivery microrobots involve disciplines such as materials science, mechanical engineering, medicine, and control systems, this paper begins by introducing the gastrointestinal barriers that oral drug delivery must overcome. Subsequently, it provides an overview of typical materials involved in the design process of oral drug delivery microrobots. To enhance readers' understanding of the working principles and design process of oral drug delivery microrobots, we present a guideline for designing such microrobots. Furthermore, the current development status of various types of oral drug delivery microrobots is reviewed, summarizing their respective advantages and limitations. Finally, considering the significant concerns regarding safety and clinical translation, we discuss the challenges and prospections of clinical translation for various oral drug delivery microrobots presented in this paper, providing corresponding suggestions for addressing some existing challenges.
Mutational landscape and tumour mutational burden in adults with malignant melanoma arising from congenital naevi
Authors: Grace B Hanrahan, Hillary C Tsibris
Journal: British Journal of Dermatology (2024)

We evaluated the genetic mutations, tumour mutational burden (TMB) and ultraviolet (UV) signature pattern in melanomas arising in congenital melanocytic naevi (CMN) in adults treated at the Dana–Farber Cancer Institute. Whereas paediatric CMN melanomas are characterized by NRAS mutations and reportedly lack BRAF and PTEN mutations, analysis showed that adult CMN melanomas contain BRAF, PTEN and TERT promotor mutations. Adult CMN melanomas showed low average TMB and an absent UV signature, suggesting lower UV damage in adult CMN melanoma than in other subtypes. Patients treated with immune checkpoint inhibition showed refractory disease progression, potentially attributable to low TMB. Findings suggest adult CMN melanoma may have distinct genetic properties from paediatric CMN melanoma and show immunotherapy resistance.
Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease
Authors: Takuma Nakatsuka, Ryosuke Tateishi, Masaya Sato, Natsuka Hashizume, Ami Kamada, Hiroki Nakano, Yoshinori Kabeya, Sho Yonezawa, Rie Irie, Hanako Tsujikawa, Yoshio Sumida, Masashi Yoneda, Norio Akuta, Takumi Kawaguchi, Hirokazu Takahashi, Yuichiro Eguchi, Yuya Seko, Yoshito Itoh, Eisuke Murakami, Kazuaki Chayama, Makiko Taniai, Katsutoshi Tokushige, Takeshi Okanoue, Michiie Sakamoto, Mitsuhiro Fujishiro, Kazuhiko Koike
Journal: Hepatology (2024)

Background and Aims: Identifying patients with steatotic liver disease who are at a high risk of developing HCC remains challenging. We present a deep learning (DL) model to predict HCC development using hematoxylin and eosin-stained whole-slide images of biopsy-proven steatotic liver disease. Approach and Results: We included 639 patients who did not develop HCC for ≥7 years after biopsy (non-HCC class) and 46 patients who developed HCC &lt;7 years after biopsy (HCC class). Paired cases of the HCC and non-HCC classes matched by biopsy date and institution were used for training, and the remaining nonpaired cases were used for validation. The DL model was trained using deep convolutional neural networks with 28,000 image tiles cropped from whole-slide images of the paired cases, with an accuracy of 81.0% and an AUC of 0.80 for predicting HCC development. Validation using the nonpaired cases also demonstrated a good accuracy of 82.3% and an AUC of 0.84. These results were comparable to the predictive ability of logistic regression model using fibrosis stage. Notably, the DL model also detected the cases of HCC development in patients with mild fibrosis. The saliency maps generated by the DL model highlighted various pathological features associated with HCC development, including nuclear atypia, hepatocytes with a high nuclear-cytoplasmic ratio, immune cell infiltration, fibrosis, and a lack of large fat droplets. Conclusions: The ability of the DL model to capture subtle pathological features beyond fibrosis suggests its potential for identifying early signs of hepatocarcinogenesis in patients with steatotic liver disease.
Prostate cancer-derived extracellular vesicles metabolic biomarkers: Emerging roles for diagnosis and prognosis
Authors: Mahmoud Assem Hamed, Valerie Wasinger, Qi Wang, Peter Graham, David Malouf, Joseph Bucci, Yong Li
Journal: Journal of Controlled Release (2024)

Prostate cancer (PCa) is a global health concern, ranking as the most common cancer among men in Western countries. Traditional diagnostic methods are invasive with adverse effects on patients. Due to the heterogeneous nature of PCa and their multifocality, tissue biopsies often yield false-negative results. To address these challenges, researchers are exploring innovative approaches, particularly in the realms of proteomics and metabolomics, to identify more reliable biomarkers and improve PCa diagnosis. Liquid biopsy (LB) has emerged as a promising non-invasive strategy for PCa early detection, biopsy selection, active surveillance for low-risk cases, and post-treatment and progression monitoring. Extracellular vesicles (EVs) are lipid-bilayer nanovesicles released by all cell types and play an important role in intercellular communication. EVs have garnered attention as a valuable biomarker resource in LB for PCa-specific biomarkers, enhancing diagnosis, prognostication, and treatment guidance. Metabolomics provides insight into the body's metabolic response to both internal and external stimuli, offering quantitative measurements of biochemical alterations. It excels at detecting non-genetic influences, aiding in the discovery of more accurate cancer biomarkers for early detection and disease progression monitoring. This review delves into the potential of EVs as a resource for LB in PCa across various clinical applications. It also explores cancer-related metabolic biomarkers, both within and outside EVs in PCa, and summarises previous metabolomic findings in PCa diagnosis and risk assessment. Finally, the article addresses the challenges and future directions in the evolving field of EV-based metabolomic analysis, offering a comprehensive overview of its potential in advancing PCa management.
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study
Authors: Stanislas Pol, Alexander J. Thompson, Michelle Collins, Elisa Venier, Laurent Cotte, Montserrat Laguno Centeno, Jorge Mera, Thomas Reiberger, Margaret Burroughs, Dimitri G. Semizarov, Alexandru M. Iacob, Anne Welhaven, Linda M. Fredrick, Joseph S. Doyle
Journal: Hepatology (2024)

Background and Aims: No direct-acting antiviral is currently approved for acute HCV infection, delaying treatment. We investigated the effectiveness and safety of 8-week glecaprevir/pibrentasvir (G/P) in patients with acute HCV infection. Approach and Results: This noninterventional, single-arm, retrospective chart review was designed to enroll adults/adolescents with acute HCV infection. Analyses were conducted on a full analysis set (FAS; all enrolled) and modified FAS (FAS excluding nonvirologic failures). The primary end point (modified FAS) was sustained virologic response at posttreatment week 12 (SVR12) with superiority to 92.6% threshold determined by historic chronic HCV G/P SVR12 rates. Secondary end points (FAS) included SVR12, on-treatment virologic failure, posttreatment relapse, and reinfection. Adverse events and safety laboratory values were assessed. Overall, 202 adults were enrolled; in the modified FAS, 150/151 (99.3%; 95% CI: 96.3–99.9) achieved SVR12, demonstrating superiority to efficacy threshold. In the FAS, the SVR12 rate was 74.3% and the on-treatment virologic failure rate was 0%. Relapse and reinfection rates after the final treatment visit (FAS) were 0.5% and 3%, respectively; 39 patients had missing SVR12 data. No on-treatment alanine aminotransferase elevations &gt; 3 × upper limit of normal with total bilirubin &gt; 2 × upper limit of normal were reported. All 53 patients with alanine aminotransferase Grade ≥ 2 at baseline improved to Grade 0/1 on treatment. No adverse eventss of hepatic decompensation/failure or leading to G/P discontinuation occurred. Two patients had serious adverse events unrelated to G/P. Conclusions: Eight-week G/P therapy was effective and well-tolerated in patients with acute HCV infection. Data support further investigation of G/P in acute HCV to shorten care cascades, reduce transmission, and support HCV elimination.
Post-Roe v Wade psychiatry: legal, clinical, and ethical challenges in psychiatry under abortion bans
Authors: Nina V Kraguljac, Debra P Bruns, Paul S Appelbaum, Erika Botello, Victoria L King, Natalie Remiszewski, Alik S Widge, Jonathan E Alpert, Linda L Carpenter, Adrienne Grzenda, John H Krystal, William M McDonald, Charles B Nemeroff
Journal: The Lancet Psychiatry (2024)
Analysis of admixed Greenlandic siblings shows that the mean genotypic values for metabolic phenotypes differ between Inuit and Europeans
Authors: Long Lin, Mette K. Andersen, Frederik Filip Stæger, Zilong Li, Kristian Hanghøj, Allan Linneberg, Niels Grarup, Marit Eika Jørgensen, Torben Hansen, Ida Moltke, Anders Albrechtsen
Journal: Genome Medicine (2024)

Disease prevalence and mean phenotype values differ between many populations, including Inuit and Europeans. Whether these differences are partly explained by genetic differences or solely due to differences in environmental exposures is still unknown, because estimates of the genetic contribution to these means, which we will here refer to as mean genotypic values, are easily confounded, and because studies across genetically diverse populations are lacking. Leveraging the unique genetic properties of the small, admixed and historically isolated Greenlandic population, we estimated the differences in mean genotypic value between Inuit and European genetic ancestry using an admixed sibling design. Analyses were performed across 26 metabolic phenotypes, in 1474 admixed sibling pairs present in a cohort of 5996 Greenlanders. After FDR correction for multiple testing, we found significantly lower mean genotypic values in Inuit genetic ancestry compared to European genetic ancestry for body weight (effect size per percentage of Inuit genetic ancestry (se), -0.51 (0.16) kg/%), body mass index (-0.20 (0.06) kg/m2/%), fat percentage (-0.38 (0.13) %/%), waist circumference (-0.42 (0.16) cm/%), hip circumference (-0.38 (0.11) cm/%) and fasting serum insulin levels (-1.07 (0.51) pmol/l/%). The direction of the effects was consistent with the observed mean phenotype differences between Inuit and European genetic ancestry. No difference in mean genotypic value was observed for height, markers of glucose homeostasis, or circulating lipid levels. We show that mean genotypic values for some metabolic phenotypes differ between two human populations using a method not easily confounded by possible differences in environmental exposures. Our study illustrates the importance of performing genetic studies in diverse populations.
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review
Authors: Adam B. Weiner, Preeti Kakani, Andrew J. Armstrong, Alberto Bossi, Philip Cornford, Felix Feng, Pratik Kanabur, R. Jeffery Karnes, Rana R. Mckay, Todd M. Morgan, Edward M. Schaeffer, Neal Shore, Alison C. Tree, Daniel E. Spratt
Journal: European Urology (2024)
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Authors: I. Melero, T. Yau, Y.-K. Kang, T.-Y. Kim, A. Santoro, B. Sangro, M. Kudo, M.-M. Hou, A. Matilla, F. Tovoli, J. Knox, A.R. He, B. El-Rayes, M. Acosta-Rivera, H.Y. Lim, S. Soleymani, J. Yao, J. Neely, M. Tschaika, C. Hsu, A.B. El-Khoueiry
Journal: Annals of Oncology (2024)

Nivolumab plus ipilimumab demonstrated promising clinical activity and durable responses in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC) in the CheckMate 040 study at 30.7-month median follow-up. Here, we present 5-year results from this cohort.
Volunteerism Addressing Environmental Disparities in Allergy (VAEDIA): The presidential initiative to combat environmental injustice in allergy and immunology—a Work Group Report of the AAAAI VAEDIA task force
Authors: Mahboobeh Mahdavinia, Jill A. Poole, Andrea J. Apter, Susan E. Pacheco, Andrea A. Pappalardo, Elizabeth C. Matsui, Carla M. Davis, Jonathan A. Bernstein
Journal: Journal of Allergy and Clinical Immunology (2024)
Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
Authors: Kelly N. Fitzgerald, Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Laura Peralta, Yingbei Chen, Robert A. Lefkowitz, Neil J. Shah, Colette N. Owens, Deaglan J. McHugh, David H. Aggen, Andrew L. Laccetti, Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer
Journal: European Urology (2024)
Societal implications of the Dobbs v Jackson Women's Health Organization decision
Authors: Claire D Brindis, Melissa H Laitner, Ellen Wright Clayton, Susan C Scrimshaw, Barbara J Grosz, Lisa A Simpson, Sara Rosenbaum, Corale L Brierley, Melissa A Simon, Yvette Roubideaux, Bruce N Calonge, Paula A Johnson, Laura DeStefano, Ashley Bear, Kavita S Arora, Victor J Dzau
Journal: The Lancet (2024)
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Authors: Alexa B Kimball, Gregor B E Jemec, Christopher J Sayed, Joslyn S Kirby, Errol Prens, John R Ingram, Amit Garg, Alice B Gottlieb, Jacek C Szepietowski, Falk G Bechara, Evangelos J Giamarellos-Bourboulis, Hideki Fujita, Robert Rolleri, Paulatsya Joshi, Pratiksha Dokhe, Edward Muller, Luke Peterson, Cynthia Madden, Muhammad Bari, Christos C Zouboulis
Journal: The Lancet (2024)
Prediction of diagnosis and diastolic filling pressure by AI-enhanced cardiac MRI: a modelling study of hospital data
Authors: David Hermann Lehmann, Bruna Gomes, Niklas Vetter, Olivia Braun, Ali Amr, Thomas Hilbel, Jens Müller, Ulrich Köthe, Christoph Reich, Elham Kayvanpour, Farbod Sedaghat-Hamedani, Manuela Meder, Jan Haas, Euan Ashley, Wolfgang Rottbauer, Dominik Felbel, Raffi Bekeredjian, Heiko Mahrholdt, Andreas Keller, Peter Ong, Andreas Seitz, Hauke Hund, Nicolas Geis, Florian André, Sandy Engelhardt, Hugo A Katus, Norbert Frey, Vincent Heuveline, Benjamin Meder
Journal: The Lancet Digital Health (2024)
Kenneth Ira Berns
Authors: Sanjeet Bagcchi
Journal: The Lancet Infectious Diseases (2024)

passed away on Jan 26, 2024, in Gainesville (FL, USA), aged 85 years.Berns received substantial acclaim for his work on adeno-associated virus (AAV), a virus that has gained attention due to its utility in gene therapy.Berns carried out important studies relating to AAV's life cycle, DNA replication, genetic expression regulation, and integration of the AAV genome.A review on AAV that was coauthored by Berns in 2008 noted that, "AAV remains a promising delivery system for the realisation of the dream of gene therapy.It compares favourably to other viral vectors, especially when sustained transgene expression is desired."
Expanding the knowledge of tumour necrosis factor-α-induced gasdermin E-mediated pyroptosis in psoriasis
Authors: Helen Vaher
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Expanding the knowledge about the TNF-α induced GSDME-mediated pyroptosis in psoriasis Get access Helen Vaher Helen Vaher The LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, The University of Copenhagen, Copenhagen, Denmark Email:helen.vaher@sund.ku.dk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae223, https://doi.org/10.1093/bjd/ljae223 Published: 23 May 2024 Article history Received: 15 May 2024 Accepted: 22 May 2024 Published: 23 May 2024
Receipt of Diabetes Specialty Care and Management Services by Older Adults With Diabetes in the United States, 2015–2019: An Analysis of Medicare Fee-for-Service Claims
Authors: Anna R. Kahkoska, Jan Busby-Whitehead, Michele Jonsson Funk, Richard E. Pratley, Ruth S. Weinstock, Laura A. Young, Joshua M. Weinstein
Journal: Diabetes Care (2024)

OBJECTIVE We characterized the receipt of diabetes specialty care and management services among older adults with diabetes. RESEARCH DESIGN AND METHODS Using a 20% random sample of fee-for-service Medicare beneficiaries aged ≥65 years, we analyzed cohorts of type 1 diabetes (T1D) or type 2 diabetes (T2D) with history of severe hypoglycemia (HoH), and all other T2D annually from 2015 to 2019. Outcomes were receipt of office-based endocrinology care, diabetes education, outpatient diabetes health services, excluding those provided in primary care, and any of the aforementioned services. RESULTS In the T1D cohort, receipt of endocrinology care and any service increased from 25.9% and 29.2% in 2015 to 32.7% and 37.4% in 2019, respectively. In the T2D with HoH cohort, receipt of endocrinology care and any service was 13.9% and 16.4% in 2015, with minimal increases. Age, race/ethnicity, residential setting, and income were associated with receiving care. CONCLUSIONS These findings suggest that many older adults may not receive specialty diabetes care and underscore health disparities.
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis
Authors: Ryota Tamura, Yoshiharu Yamanobe, Masato Fujioka, Yukina Morimoto, Mariko Fukumura, Masato Nakaya, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Hiroyuki Ozawa, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda
Journal: Journal of Clinical Oncology (2024)

The humanized antivascular endothelial growth factor (VEGF) antibody bevacizumab (Bev) is efficacious for the treatment of NF2-related schwannomatosis (NF2), previously known as neurofibromatosis type 2. This study evaluated the safety and efficacy of a VEGF receptor (VEGFR) vaccine containing VEGFR1 and VEGFR2 peptides in patients with NF2 with progressive schwannomas (jRCTs031180184).
CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia
Authors: Francesco Mazziotta, Luca Biavati, Joseph Rimando, Sergio Rutella, Nicholas Borcherding, Sonali Parbhoo, Rupkatha Mukhopadhyay, Sayan Chowdhury, Hanna A. Knaus, Peter Valent, Hubert Hackl, Ivan M. Borrello, Bruce R. Blazar, Katerina Hatzi, Ivana Gojo, Leo Luznik
Journal: Blood (2024)
Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia
Authors: Richard I. Lewis, Alexander F. vom Stein, Michael Hallek
Journal: Blood (2024)

The introduction of BTK inhibitors and BCL2 antagonists to the treatment of chronic lymphocytic leukemia (CLL) has revolutionized therapy and improved patient outcomes. These agents have replaced chemoimmunotherapy as standard of care. Despite this progress, a new group of patients is currently emerging, which has become refractory or intolerant to both classes of agents, creating an unmet medical need. Here, we propose that the targeted modulation of the tumor microenvironment provides new therapeutic options for this group of double-refractory patients. Furthermore, we outline a sequential strategy for tumor microenvironment-directed combination therapies in CLL that can be tested in clinical protocols.
Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma
Authors: Mihir Gupta, Joseph D. Bradley, Elie Massaad, Evan J. Burns, N. Zeke Georgantas, Garrett E. Maron, Julie M. Batten, Aidan Gallagher, Julia Thierauf, Naema Nayyar, Amanda Gordon, SooAe S. Jones, Michelle Pisapia, Ying Sun, Pamela S. Jones, Fred G. Barker, William T. Curry, Rajiv Gupta, Javier M. Romero, Nancy Wang, Priscilla K. Brastianos, Maria Martinez-Lage, Kensuke Tateishi, Deborah A. Forst, Brian V. Nahed, Tracy T. Batchelor, Lauren L. Ritterhouse, Florian Iser, Tobias Kessler, Justin T. Jordan, Jorg Dietrich, Matthew Meyerson, Daniel P. Cahill, Jochen K. Lennerz, Bob S. Carter, Ganesh M. Shankar
Journal: Blood (2024)

Delays and risks associated with neurosurgical biopsies preclude timely diagnosis and treatment of central nervous system (CNS) lymphoma and other CNS neoplasms. We prospectively integrated targeted rapid genotyping of cerebrospinal fluid (CSF) into the evaluation of 70 patients with CNS lesions of unknown cause. Participants underwent genotyping of CSF-derived DNA using a quantitative polymerase chain reaction-based approach for parallel detection of single-nucleotide variants in the MYD88, TERT promoter, IDH1, IDH2, BRAF, and H3F3A genes within 80 minutes of sample acquisition. Canonical mutations were detected in 42% of patients with neoplasms, including cases of primary and secondary CNS lymphoma, glioblastoma, IDH-mutant brainstem glioma, and H3K27M-mutant diffuse midline glioma. Genotyping results eliminated the need for surgical biopsies in 7 of 33 cases (21.2%) of newly diagnosed neoplasms, resulting in significantly accelerated initiation of disease-directed treatment (median, 3 vs 12 days; P = .027). This assay was then implemented in a Clinical Laboratory Improvement Amendments environment, with 2-day median turnaround for diagnosis of CNS lymphoma from 66 patients across 4 clinical sites. Our study prospectively demonstrates that targeted rapid CSF genotyping influences oncologic management for suspected CNS tumors.
Myocardial Mitochondrial Function Is Impaired in Cardiac Light-Chain Amyloidosis Compared to Transthyretin Amyloidosis
Authors: Fabian Voß, Elric Zweck, Rojda Ipek, Heinz-Peter Schultheiss, Michael Roden, Malte Kelm, Julia Szendroedi, Amin Polzin, Ralf Westenfeld, Daniel Scheiber
Journal: JACC Heart Failure (2024)